The Oncology Institute, Inc. (TOI) Misses Q3 EPS by 1c; Offers FY22 Revenue Guidance

The Oncology Institute, Inc. (NASDAQ: TOI) reported Q3 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $65 million versus the consensus estimate of $68.91 million.

GUIDANCE:

The Oncology Institute, Inc. sees FY2022 revenue of $245-250 million, versus the consensus of $270.3 million.

For earnings history and earnings-related data on The Oncology Institute, Inc. (TOI) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• C.H. Robinson acquires DeSpir Logistics for $75 million